{"id":"erlotinib-chlorhydrate","safety":{"commonSideEffects":[{"rate":"75","effect":"Rash/dermatitis"},{"rate":"54","effect":"Diarrhea"},{"rate":"40","effect":"Nausea"},{"rate":"52","effect":"Fatigue"},{"rate":"52","effect":"Anorexia"},{"rate":"29","effect":"Vomiting"},{"rate":"1","effect":"Interstitial lung disease"}]},"_chembl":{"chemblId":"CHEMBL1079742","moleculeType":"Small molecule","molecularWeight":"429.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Erlotinib selectively inhibits the intracellular tyrosine kinase domain of EGFR, preventing autophosphorylation and downstream signaling through the MAPK and PI3K/AKT pathways. This leads to cell cycle arrest and apoptosis in EGFR-dependent tumors. It is particularly effective in non-small cell lung cancers harboring activating EGFR mutations.","oneSentence":"Erlotinib is a small-molecule tyrosine kinase inhibitor that blocks epidermal growth factor receptor (EGFR) signaling to inhibit cancer cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:20.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC) with EGFR mutations"},{"name":"Pancreatic cancer (in combination with gemcitabine)"}]},"trialDetails":[{"nctId":"NCT00442455","phase":"PHASE3","title":"Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Grupo de Investigación Clínica en Oncología Radioterapia","startDate":"2006-01","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Erlotinib clorhidrate"],"phase":"phase_3","status":"active","brandName":"Erlotinib chlorhydrate","genericName":"Erlotinib chlorhydrate","companyName":"Grupo de Investigación Clínica en Oncología Radioterapia","companyId":"grupo-de-investigaci-n-cl-nica-en-oncolog-a-radioterapia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Erlotinib is a small-molecule tyrosine kinase inhibitor that blocks epidermal growth factor receptor (EGFR) signaling to inhibit cancer cell proliferation. Used for Non-small cell lung cancer (NSCLC) with EGFR mutations, Pancreatic cancer (in combination with gemcitabine).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}